

Cationic Glyco-nanogels for Epidermal Growth Factor Receptor (EGFR) specific siRNA delivery in Ovarian Cancer Cells

Marya Ahmed[†], Phanphen Wattanaarsakit[§], Ravin Narain^{†}*

*[†]Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 2G6,
Canada*

*[§]Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences,
Chulalongkorn University, Phyathai Road, Pathumwan, Bangkok, Thailand*

Table S1. Preparation of nanogels

Nanogels	PEGMA or NIPAM (mg)	AEMA (mg)	Macro-CTAs (mg)	CL (mg)	ACVA (mg)
NGA1	301	66	380	60	2
NGA2	200	73	165	133	1.6

NGA1: GAEMA₆₃-*b*-(MeODEGM-*st*-AEMA-*st*-CL)₁₀₀



NGA2: GAPMA₅₇-*b*-(NIPAM-*st*-AEMA-*st*-CL)₂₀₀




Figure S1: Complexation of β -galactosidase DNA with cationic glyco-nanogels, at varying w/w ratios.




Figure S2: Size of nanogel-siRNA complexes in OMEM media in the absence and presence of serum proteins, as determined by DLS analysis.